Publications（2010〜2022）

2022

1. 1Zhang H, Itoh Y, Suzuki T, Ihara KI, Tanaka T, Haga S, Enatsu H, Yumiya M, Kimura M, Takada A, Itoh D, Shibazaki Y, Nakao S, Yoshio S, Miyakawa K, Miyamoto Y, Sasaki H, Kajita T, Sugiyama M, Mizokami M, Tachibana T, Ryo A, Moriishi K, Miyoshi E, Kanto T, Okamoto T, Matsuura Y: Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus. Microbiol Immunol, 66: 179-192, 2022: doi:10.1111/1348-0421.12964.
   

2. 2Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, Aly HH, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Goh Y, Ishii KJ, Yotsuyanagi H, Muramatsu M, Ishii K, Takahashi Y, Suzuki R, Akari H, Kato T: Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. Nat Commun, 13: 5207, 2022: doi:10.1038/s41467-022-32910-z.
   

3. 3Toyama M, Watashi K, Ikeda M, Yamashita A, Okamoto M, Moriishi K, Muramatsu M, Wakita T, Sharon A, Baba M: Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action. Antimicrobial Agents & Chemotherapy, 66: e0207321, 2022: doi:10.1128/aac.02073-21.
   

4. 4Tanaka T, Saito A, Suzuki T, Miyamoto Y, Takayama K, Okamoto T, Moriishi K: Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. Antiviral Res, 199: 105268, 2022: doi:10.1016/j.antiviral.2022.105268.
   

5. 5Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S, Tanaka T, Kume Y, Chishiki M, Ono T, Moriishi K, Sonoyama M, Hosoya M, Hashimoto K, Maenaka K, Takeda M: Hydrophobic Alpha-Helical Short Peptides in Overlapping Reading Frames of the Coronavirus Genome. Pathogens, 11: 877, 2022: doi:10.3390/pathogens11080877.
   

6. 6Miyamoto Y, Itoh Y, Suzuki T, Tanaka T, Sakai Y, Koido M, Hata C, Wang CX, Otani M, Moriishi K, Tachibana T, Kamatani Y, Yoneda Y, Okamoto T, Oka M: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication. Commun Biol, 5: 483, 2022: doi:10.1038/s42003-022-03427-4.
   

2021

1. 1Otoguro T, Tanaka T, Kasai H, Kobayashi N, Yamashita A, Fukuhara T, Ryo A, Fukai M, Taketomi A, Matsuura Y, Moriishi K. 2021. Establishment of a cell culture model permissive for infection by hepatitis B and C viruses. Hepatol Commun, 5: 634-649, 2021: doi:10.1002/hep4.1653.
   
   

2. 2Tanaka T, Okuyama-Dobashi K, Motohashi R, Yokoe H, Takahashi K, Wiriyasermkul P, Kasai H, Yamashita A, Maekawa S, Enomoto N, Ryo A, Nagamori S, Tsubuki M, Moriishi K: Inhibitory effect of a novel thiazolidinedione derivative on hepatitis B virus entry. Antiviral Res, 194: 105165, 2021: doi:10.1016/j.antiviral.2021.105165.
   
   

3. 3Yato K, Onodera T, Matsuda M, Moriyama S, Fujimoto A, Watashi K, Aizaki H, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Tamura K, Takahashi Y, Wakita T, Muramatsu M, Kato T, Suzuki R: Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1. J Virol, 95: e01680-20, 2021: doi:10.1128/JVI.01680-20.
   
   

4. 4Murayama A, Yamada N, Osaki Y, Shiina M, Aly HH, Iwamoto M, Tsukuda S, Watashi K, Matsuda M, Suzuki R, Tanaka T, Moriishi K, Suzuki T, Nishitsuji H, Sugiyama M, Mizokami M, Shimotohno K, Wakita T, Muramatsu M, Liang TJ, Kato T: N-Terminal PreS1 Sequence Regulates Efficient Infection of Cell-Culture-Generated Hepatitis B Virus. Hepatology, 73: 520-532, 2021: doi:10.1002/hep.31308.
   
   

5. 5Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N: Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy. Hepatol Res, 51: 39-50, 2021: doi:10.1111/hepr.13574.
   
   

6. 6Kasai H, Mochizuki K, Tanaka T, Yamashita A, Matsuura Y, Moriishi K: Induction of HOX Genes by Hepatitis C Virus Infection via Impairment of Histone H2A Monoubiquitination. J Virol, 95: e01784-20, 2021: doi:10.1128/JVI.01784-20.
   
   

7. 7Izumi T, Morioka Y, Urayama SI, Motooka D, Tamura T, Kawagishi T, Kanai Y, Kobayashi T, Ono C, Morinaga A, Tomiyama T, Iseda N, Kosai Y, Inokuchi S, Nakamura S, Tanaka T, Moriishi K, Kariwa H, Yoshizumi T, Mori M, Matsuura Y, Fukuhara T: DsRNA Sequencing for RNA Virus Surveillance Using Human Clinical Samples. Viruses, 13: 1310, 2021: doi:10.3390/v13071310.
   
   

8. 8Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T: Amino Acid Polymorphism in Hepatitis B Virus Associated with Functional Cure. Cell Mol Gastroenterol Hepatol, in press: 2021: doi:10.1016/j.jcmgh.2021.07.013.
   
   

9. 9Hirano J, Yoshio S, Sakai Y, Songling L, Suzuki T, Itoh Y, Zhang H, Chen DV, Haga S, Oomori H, Kodama T, Maeda Y, Ono Y, Takahashi Y, Standley DM, Yamamoto M, Moriishi K, Moriya K, Kanto T, Takehara T, Koike K, Matsuura Y, Okamoto T: Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proc Natl Acad Sci U S A, 118: e2026184118, 2021: doi:10.1073/pnas.2026184118.
   

2020

1. 1Akahori Y, Kato H, Fujita T, Moriishi K, Tanaka Y, Watashi K, Imamura M, Chayama K, Wakita T, Hijikata M. 2020. Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes. Sci Rep 10:21718.
   
   

2. 2Yamada N, Murayama A, Shiina M, Aly HH, Iwamoto M, Tsukuda S, Watashi K, Tanaka T, Moriishi K, Nishitsuji H, Sugiyama M, Mizokami M, Shimotohno K, Muramatsu M, Murata K, Kato T. 2020. Anti-viral effects of interferon-lambda3 on hepatitis B virus infection in cell culture. Hepatol Res 50:283-291.
   
   

3. 3Muraoka M, Maekawa S, Suzuki Y, Sato M, Tatsumi A, Matsuda S, Miura M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Yamashita A, Moriishi K, Matsuda M, Enomoto N. 2020. Cancer-related genetic changes in multistep hepatocarcinogenesis and their correlation with imaging and histological findings. Hepatol Res 50(9):1071-1082. doi: 10.1111/hepr.13529.
   
   

4. 4Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N. 2020. Deep Sequencing Analysis of Serum Hepatitis B Virus-RNA During Nucleoside Analogue Therapy. Hepatol Res 51(1):39-50. doi: 10.1111/hepr.13574.
   
   

2019

1. 1Kusakabe S, Suzuki T, Sugiyama Y, Haga S, Horike K, Tokunaga M, Hirano J, Zhang H, Chen DV, Ishiga H, Komoda Y, Ono C, Fukuhara T, Yamamoto M, Ikawa M, Satoh T, Akira S, Tanaka T, Moriishi K, Fukai M, Taketomi A, Yoshio S, Kanto T, Suzuki T, Okamoto T, Matsuura Y. 2019. USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation. J Virol 93:e01708-18.
   
   

2. 2Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2019. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res 49:51-63.
   
   

3. 3Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2019. HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers. PLoS One 14:e0212559.
   
   

4. 4Katoh I, Tanabe F, Kasai H, Moriishi K, Shimasaki N, Shinohara K, Uchida Y, Koshiba T, Arakawa S, Morimoto M: Potential Risk of Virus Carryover by Fabrics of Personal Protective Gowns. Front Public Health, 7: 121, 2019,
   
   

5. 5Katoh I, Maehata Y, Moriishi K, Hata RI, Kurata SI: C-terminal alpha Domain of p63 Binds to p300 to Coactivate beta-Catenin. Neoplasia, 21: 494-503, 2019
   
   

2018

1. 1Tanaka T, Otoguro T, Kasai H, Yamashita A, Fukuhara T, Matsuura Y, Moriishi K. 2018. Roles of the 5’ untranslated region of non-primate hepacivirus in translation initiation and viral replication. J Virol. 92: pill: e01997-17.
   
   

2. 2Hayashi S, Tanaka T, Moriishi K, Hirayama K, Yamada A, Hotta K. 2017. Seroepidemiology of non-primate hepacivirus (NPHV) in Japanese native horses. J Vet Med Sci. 80:186-189.
   
   

2017

1. 1.Yasumoto J, Kasai H, Yoshimura K, Otoguro T, Watashi K, Wakita T, Yamashita A, Tanaka T, Takeda S, Moriishi K. 2017. Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors. J Gen Virol 98:1762-1773.
   

2. 2.Yamashita A, Tamaki M, Kasai H, Tanaka T, Otoguro T, Ryo A, Maekawa S, Enomoto N, de Voogd NJ, Tanaka J, Moriishi K. 2017. Inhibitory effects of metachromin A on hepatitis B virus production via impairment of the viral promoter activity. Antiviral Res 145:136-145.
   

3. 3.Amano R, Yamashita A, Kasai H, Hori T, Miyasato S, Saito S, Yokoe H, Takahashi K, Tanaka T, Otoguro T, Maekawa S, Enomoto N, Tsubuki M, Moriishi K. 2017. Cinnamic acid derivatives inhibit hepatitis C virus replication via the induction of oxidative stress. Antiviral Res 145:123-130.
   

4. 4.Moriishi K. 2017. The potential of signal peptide peptidase as a therapeutic target for hepatitis C. Expert Opin Ther Targets 21:827-836.
   

5. 5.Schaefer B, Moriishi K, Behrends S. 2017. Insights into the mechanism of isoenzyme-specific signal peptide peptidase-mediated translocation of heme oxygenase. PLoS One 12:e0188344.
   

6. 6.Matsuzawa T, Ogawa Y, Moriishi K, Shimada S, Kawamura T. 2017. Immunological function of Langerhans cells in HIV infection. J Dermatol Sci 87:159-167.
   

7. 7.Hirano J, Okamoto T, Sugiyama Y, Suzuki T, Kusakabe S, Tokunaga M, Fukuhara T, Sasai M, Tougan T, Matsunaga Y, Yamashita K, Sakai Y, Yamamoto M, Horii T, Standley DM, Moriishi K, Moriya K, Koike K, Matsuura Y. 2017. Characterization of SPP inhibitors suppressing propagation of HCV and protozoa. Proc Natl Acad Sci U S A 114:E10782-E10791.
   

8. 8.Hermawan I, Furuta A, Higashi M, Fujita Y, Akimitsu N, Yamashita A, Moriishi K, Tsuneda S, Tani H, Nakakoshi M, Tsubuki M, Sekiguchi Y, Noda N, Tanaka J. 2017. Four Aromatic Sulfates with an Inhibitory Effect against HCV NS3 Helicase from the Crinoid Alloeocomatella polycladia. Mar Drugs 15:117.
   

9. 9.Amano R, Yamashita A, Kasai H, Hori T, Miyasato S, Saito S, Tsubuki M, Moriishi K. 2017. Catechol group of cinnamic acid derivative is essential for its anti-hepatitis C virus activity.  Yamanashi Medical Journal 32:95 - 103.
   

10. 10.Amano R, Moriishi K. 2017. Hepatitis C virus and oxidative stress (in Japanese). Yamanashi Medical Journal 32:87 - 93.
    

2016

1. 1.Tanaka T, Okuyama-Dobashi K, Murakami S, Chen W, Okamoto T, Ueda K, Hosoya T, Matsuura Y, Ryo A, Tanaka Y, Hagiwara M, Moriishi K. 2016. Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation. Antiviral Res 133:156-164.
   

2. 2.Otoguro T, Tanaka T, Kasai H, Yamashita A, Moriishi K. 2016. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol 60:740-753.
   

3. 3.Moriishi K, Matsuura Y. 2016. Structural Proteins of HCV and Biological Functions, p 105 - 128. In Miyamura T, Lemon SM, Walker CM, Wakita T (ed), Hepatitis C virus I: Cellular and Molecular Virology doi:ISBN-10: 978-4431560982ISBN-13: 978-4431560968. Springer.
   

4. 4.Kouwaki T, Okamoto T, Ito A, Sugiyama Y, Yamashita K, Suzuki T, Kusakabe S, Hirano J, Fukuhara T, Yamashita A, Saito K, Okuzaki D, Watashi K, Sugiyama M, Yoshio S, Standley DM, Kanto T, Mizokami M, Moriishi K, Matsuura Y. 2016. Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx. J Virol 90:3530-3542.
   

5. 5.Katoh I, Fukunishi N, Fujimuro M, Kasai H, Moriishi K, Hata R, Kurata S. 2016. Repression of Wnt/beta-catenin response elements by p63 (TP63). Cell Cycle 15:699-710.
   

6. 6.Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Moriishi K, Nakao A, Shimada S. 2016. The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell-Mediated Antiviral Innate Immunity. J Invest Dermatol 136:1290-1292.
   

7. 7.Aizawa S, Okamoto T, Sugiyama Y, Kouwaki T, Ito A, Suzuki T, Ono C, Fukuhara T, Yamamoto M, Okochi M, Hiraga N, Imamura M, Chayama K, Suzuki R, Shoji I, Moriishi K, Moriya K, Koike K, Matsuura Y. 2016. TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis. Nature Communications 7:11379.
   

2015

1. 1.Yamashita A, Fujimoto Y, Tamaki M, Setiawan A, Tanaka T, Okuyama-Dobashi K, Kasai H, Watashi K, Wakita T, Toyama M, Baba M, de Voogd NJ, Maekawa S, Enomoto N, Tanaka J, Moriishi K. 2015. Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay. Mar Drugs 13:6759-6773.
   

2. 2.Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2015. Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus. J Virol 89:6105-6116.
   

3. 3.Okuyama-Dobashi K, Kasai H, Tanaka T, Yamashita A, Yasumoto J, Chen W, Okamoto T, Maekawa S, Watashi K, Wakita T, Ryo A, Suzuki T, Matsuura Y, Enomoto N, Moriishi K. 2015. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci Rep 5:17047.
   

4. 4.Nghia NA, Hirasawa T, Kasai H, Obata C, Moriishi K, Mochizuki K, Koizumi S, Kubota T. 2015. Long-term imipramine treatment increases N-methyl-D-aspartate receptor activity and expression via epigenetic mechanisms. Eur J Pharmacol 752:69-77.
   

5. 5.Maeyama H, Hirasawa T, Tahara Y, Obata C, Kasai H, Moriishi K, Mochizuki K, Kubota T. 2015. Maternal restraint stress during pregnancy in mice induces 11 beta-HSD1-associated metabolic changes in the livers of the offspring. J Dev Orig Health Dis 6:105-114.
   

6. 6.Kasai H, Kawakami K, Yokoe H, Yoshimura K, Matsuda M, Yasumoto J, Maekawa S, Yamashita A, Tanaka T, Ikeda M, Kato N, Okamoto T, Matsuura Y, Sakamoto N, Enomoto N, Takeda S, Fujii H, Tsubuki M, Kusunoki M, Moriishi K. 2015. Involvement of FKBP6 in hepatitis C virus replication. Sci Rep 5:16699.
   

7. 7.Ito S, Hirabayashi K, Moriishi K, Matsui Y, Moriya K, Koike K, Matsuura Y, Shiota K, Yagi S. 2015. Novel sex-dependent differentially methylated regions are demethylated in adult male mouse livers. Biochem Biophys Res Commun 462:332-338.
   

8. 8.Furuta A, Tsubuki M, Endoh M, Miyamoto T, Tanaka J, Salam KA, Akimitsu N, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Sekiguchi Y, Tsuneda S, Noda N. 2015. Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. Int J Mol Sci 16:18439-18453.
   

2014

1. 1.Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, Maekawa S, Enomoto N, Okamoto T, Matsuura Y, Morimatsu M, Manabe N, Ochiai K, Yamashita K, Moriishi K. 2014. Hallmarks of Hepatitis C Virus in Equine Hepacivirus. J Virol 88:13352-13366.
   

2. 2.Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tani H, Roy SR, Tanaka J, Tsubuki M, Akimitsu N. 2014. PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase. Molecules 19:4006-4020.
   

3. 3.Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H. 2014. EFdA, a Reverse Transcriptase Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells within Epithelium. J Invest Dermatol 134:1158-1161.
   

4. 4.Furuta A, Salam KA, Hermawan I, Akimitsu N, Tanaka J, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Peng PW, Suzuki Y, Yamamoto N, Sekiguchi Y, Tsuneda S, Noda N. 2014. Identification and Biochemical Characterization of Halisulfate 3 and Suvanine as Novel Inhibitors of Hepatitis C Virus NS3 Helicase from a Marine Sponge. Mar Drugs 12:462-476.
   

5. 5.Furuta A, Salam KA, Akimitsu N, Tanaka J, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Noda N. 2014. Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. J Enzyme Inhib Med Chem 29:223-229.
   

6. 6.Allen SJ, Mott KR, Matsuura Y, Moriishi K, Kousoulas KG, Ghiasi H. 2014. Binding of HSV-1 Glycoprotein K (gK) to Signal Peptide Peptidase (SPP) Is Required for Virus Infectivity. Plos One 9:e85360.
   

2013

1. 1.Tripathi LP, Kambara H, Chen YA, Nishimura Y, Moriishi K, Okamoto T, Morita E, Abe T, Mori Y, Matsuura Y, Mizuguchi K. 2013. Understanding the Biological Context of NS5A-Host Interactions in HCV Infection: A Network-Based Approach. J Proteome Res 12:2537-2551.
   

2. 2.Tani J, Shimamoto S, Mori K, Kato N, Moriishi K, Matsuura Y, Tokumitsu H, Tsuchiya M, Fujimoto T, Kato K, Miyoshi H, Masaki T, Kobayashi R. 2013. Ca2+/S100 proteins regulate HCV virus NS5A-FKBP8/FKBP38 interaction and HCV virus RNA replication. Liver International 33:1008-1018.
   

3. 3.Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2013. IL-28B (IFN-lambda 3) and IFN-alpha synergistically inhibit HCV replication. J Viral Hepat 20:281-289.
   

4. 4.Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K. 2013. Inhibitory Effects of Caffeic Acid Phenethyl Ester Derivatives on Replication of Hepatitis C Virus. Plos One 8:e82299.
   

5. 5.Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Tani H, Tanaka J, Akimitsu N. 2013. Psammaplin A inhibits hepatitis C virus NS3 helicase. J Nat Med 67:765-772.
   

6. 6.Ogawa Y, Kawamura T, Matsuzawa T, Aoki R, Gee P, Yamashita A, Moriishi K, Yamasaki K, Koyanagi Y, Blauvelt A, Shimada S. 2013. Antimicrobial Peptide LL-37 Produced by HSV-2-Infected Keratinocytes Enhances HIV Infection of Langerhans Cells. Cell Host & Microbe 13:77-86.
   

7. 7.Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2013. Deep-Sequencing Analysis of the Association between the Quasispecies Nature of the Hepatitis C Virus Core Region and Disease Progression. J Virol 87:12541-12551.
   

8. 8.Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, Blauvelt A, Shimada S. 2013. Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium. J Invest Dermatol 133:2803-2805.
   

9. 9.Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2013. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. Hepatol Res 43:865-875.
   

10. 10.Imura Y, Morizawa Y, Komatsu R, Shibata K, Shinozaki Y, Kasai H, Moriishi K, Moriyama Y, Koizumi S. 2013. Microglia release ATP by exocytosis. Glia 61:1320-1330.
    

11. 11.Hashimoto K, Yamada S, Katano H, Fukuchi S, Sato Y, Kato M, Yamaguchi T, Moriishi K, Inoue N. 2013. Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta. Vaccine 31:3199-3205.
    

12. 12.Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A, Moriishi K, Nishiyama Y, Shimada S. 2013. Mast Cells Play a Key Role in Host Defense against Herpes Simplex Virus Infection through TNF-alpha and IL-6 Production. J Invest Dermatol 133:2170-2179.
    

2012

1. 1.Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K. 2012. Inhibition of Hepatitis C Virus Replication and Viral Helicase by Ethyl Acetate Extract of the Marine Feather Star Alloeocomatella polycladia. Mar Drugs 10:744-761.
   

2. 2.Tripathi LP, Kambara H, Moriishi K, Morita E, Abe T, Mori Y, Chen YA, Matsuura Y, Mizuguchi K. 2012. Proteomic Analysis of Hepatitis C Virus (HCV) Core Protein Transfection and Host Regulator PA28 gamma Knockout in HCV Pathogenesis: A Network-Based Study. J Proteome Res 11:3664-3679.
   

3. 3.Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Tani H, Tanaka J, Akimitsu N. 2012. Inhibition of Hepatitis C Virus NS3 Helicase by Manoalide. J Nat Prod 75:650-654.
   

4. 4.Moriishi K, Matsuura Y. 2012. Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol 3:54.
   

5. 5.Kondo M, Moriishi K, Wada H, Noda T, Marubashi S, Wakasa K, Matsuura Y, Doki Y, Mori M, Nagano H. 2012. Upregulation of nuclear PA28 gamma expression in cirrhosis and hepatocellular carcinoma. Exp Ther Med 3:379-385.
   

6. 6.Kataoka C, Kaname Y, Taguwa S, Abe T, Fukuhara T, Tani H, Moriishi K, Matsuura Y. 2012. Baculovirus GP64-Mediated Entry into Mammalian Cells. J Virol 86:2610-2620.
   

7. 7.Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K. 2012. Inhibition of Both Protease and Helicase Activities of Hepatitis C Virus NS3 by an Ethyl Acetate Extract of Marine Sponge Amphimedon sp. Plos One 7:e48685.
   

8. 8.Abe T, Fukuhara T, Wen XY, Ninomiya A, Moriishi K, Maehara Y, Takeuchi O, Kawai T, Akira S, Matsuura Y. 2012. CD44 Participates in IP-10 Induction in Cells in Which Hepatitis C Virus RNA Is Replicating, through an Interaction with Toll-Like Receptor 2 and Hyaluronan. J Virol 86:6159-6170.
   

2011

1. 1.Wen XY, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, Suzuki T, Tatsumi M, Moriishi K, Matsuura Y. 2011. Elimination of Hepatitis C Virus from Hepatocytes by a Selective Activation of Therapeutic Molecules. Plos One 6:e15967.
   

2. 2.Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K, Kato N, Kanto T, Hotta H. 2011. Will There Be an HCV Meeting in 2020? Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses. Gastroenterology 141:E1-E5.
   

3. 3.Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, Koike K, Moriishi K, Matsuura Y. 2011. Dysfunction of Autophagy Participates in Vacuole Formation and Cell Death in Cells Replicating Hepatitis C Virus. J Virol 85:13185-13194.
   

4. 4.Katoh I, Mirova A, Kurata S, Murakami Y, Horikawa K, Nakakuki N, Sakai T, Hashimoto K, Maruyama A, Yonaga T, Fukunishi N, Moriishi K, Hirai H. 2011. Activation of the Long Terminal Repeat of Human Endogenous Retrovirus K by Melanoma-Specific Transcription Factor MITF-M. Neoplasia 13:1081-U1133.
   

5. 5.Katoh H, Mori Y, Kambara H, Abe T, Fukuhara T, Morita E, Moriishi K, Kamitani W, Matsuura Y. 2011. Heterogeneous Nuclear Ribonucleoprotein A2 Participates in the Replication of Japanese Encephalitis Virus through an Interaction with Viral Proteins and RNA. J Virol 85:10976-10988.
   

2010

1. 1.Kambara H, Tani H, Mori Y, Abe T, Katoh H, Fukuhara T, Taguwa S, Moriishi K, Matsuura Y. 2011. Involvement of cyclophilin B in the replication of Japanese encephalitis virus. Virology 412:211-219.
   

2. 2.Tripathi LP, Kataoka C, Taguwa S, Moriishi K, Mori Y, Matsuura Y, Mizuguchi K. 2010. Network based analysis of hepatitis C virus Core and NS4B protein interactions. Mol Biosyst 6:2539-2553.
   

3. 3.Tani H, Shiokawa M, Kaname Y, Kambara H, Mori Y, Abe T, Moriishi K, Matsuura Y. 2010. Involvement of Ceramide in the Propagation of Japanese Encephalitis Virus. J Virol 84:2798-2807.
   

4. 4.Tanaka Y, Mori Y, Tani H, Abe T, Moriishi K, Kojima H, Nagano T, Okabe T, Suzuki T, Tatsumi M, Matsuura Y. 2010. Establishment of an indicator cell system for hepatitis C virus. Microbiol Immunol 54:206-220.
   

5. 5.Moriishi K, Shoji I, Mori Y, Suzuki R, Suzuki T, Kataoka C, Matsuura Y. 2010. Involvement of PA28 gamma in the Propagation of Hepatitis C Virus. Hepatology 52:411-420.
   

6. 6.Kaname Y, Tani H, Kataoka C, Shiokawa M, Taguwa S, Abe T, Moriishi K, Kinoshita T, Matsuura Y. 2010. Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64. J Virol 84:3210-3219.
   

7. 7.Ito M, Masumi A, Mochida K, Kukihara H, Moriishi K, Matsuura Y, Yamaguchi K, Mizuochi T. 2010. Peripheral B Cells May Serve as a Reservoir for Persistent Hepatitis C Virus Infection. J Innate Immun 2:607-617.